Corvus Pharmaceuticals, Inc.
No enriched coverage for $CRVS in the last 7 days.
No SEC Form 4 filings for $CRVS in the last 30 days.
See all $CRVS insider activity →Corvus Pharmaceuticals (CRVS) reported on its Q2 2026 earnings call that soquelitinib, its oral ITK inhibitor, is being tested in five diseases. In a Phase 1 atopic dermatitis cohort, 75% on 200 mg twice daily reached EASI-75 at 8 weeks vs 20% placebo. Corvus said it has $215M cash and expects Phase 2 SEERA-1 results after early 2027. R&D rose to $16M and net loss to $18M.
Corvus Pharmaceuticals (CRVS) reported Q2 2026 cash and marketable securities of $215.2 million as of June 30, 2026, including $189.4 million from a January follow-on offering. Net loss was $18.0 million versus $8.0 million a year earlier. Management said cash runway funds operations into Q2 2028 and outlined Phase III PTCL and Phase II atopic dermatitis timelines for soquelitinib.
Siemens Energy was appointed to operate Guyana’s 300 MW gas-to-energy combined-cycle plant, with operations expected in early 2027, drawing gas from ExxonMobil’s Stabroek Block. Corvus Energy will supply 40 MWh battery systems for four BC Ferries hybrid vessels. Eco Wave Power reported H1 2026 operating expenses down 9%.
Recent CRVS coverage spans earnings, financial news and corporate actions.
Positive early dermatology efficacy and durability claims can re-rate risk for CRVS, but cash burn and one-asset concentration keep downside risk elevated.
The call updates funding runway and de-risks near-term catalysts (PTCL interim futility timing, AD enrollment and top-line forecast), which can shift probability-weighted valuation.
Marine battery supply contract supports order intake and validates Dolphin NxtGen Power for hybrid-electric ferry deployments.
Near-term trading focus shifts to PTCL trial decision timing (interim futility in Q1 2027) and ongoing atopic dermatitis enrollment/data milestones.
The filing is a near-term catalyst for CRVS risk pricing via updated trial progress and a materially larger cash balance extending funding runway.
alphai scores every news story that mentions CRVS with an AI model for sentiment and relevance, and aggregates insider trades from Corvus Pharmaceuticals, Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
Corvus Pharmaceuticals (CRVS) reported on its Q2 2026 earnings call that soquelitinib, its oral ITK inhibitor, is being tested in five diseases. In a Phase 1 atopic dermatitis cohort, 75% on 200 mg twice daily reached EASI-75 at 8 weeks vs 20% placebo. Corvus said it has $215M cash and expects Phase 2 SEERA-1 results after early 2027. R&D rose to $16M and net loss to $18M.
5 min readCorvus Pharmaceuticals (CRVS) reported Q2 2026 cash and marketable securities of $215.2 million as of June 30, 2026, including $189.4 million from a January follow-on offering. Net loss was $18.0 million versus $8.0 million a year earlier. Management said cash runway funds operations into Q2 2028 and outlined Phase III PTCL and Phase II atopic dermatitis timelines for soquelitinib.
6 min readSiemens Energy was appointed to operate Guyana’s 300 MW gas-to-energy combined-cycle plant, with operations expected in early 2027, drawing gas from ExxonMobil’s Stabroek Block. Corvus Energy will supply 40 MWh battery systems for four BC Ferries hybrid vessels. Eco Wave Power reported H1 2026 operating expenses down 9%.
3 min readCorvus Pharmaceuticals (NASDAQ:CRVS) said an interim futility analysis for its PTCL Phase III trial is expected in Q1 2027, with an independent committee deciding whether to continue. Final Phase III PTCL data are still expected in late 2027. For atopic dermatitis, soquelitinib Phase I results showed EASI-75 of 75% vs 20% placebo; SIERRA-1 enrollment ends early 2027 with top-line data in Q3 2027.
6 min readCorvus Pharmaceuticals, Inc. (CRVS) filed an SEC Form 8-K — Results of Operations and Financial Condition. EXHIBIT 99.1 Corvus Pharmaceuticals Provides Business Update and Reports Second Quarter 2026 Financial Results Enrollment in soquelitinib registrational Phase 3 relapsed/refractory peripheral T-cell lymphoma (PTCL) and Phase 2 atopic dermatitis trials on track Soquelitinib’s pote
5 min readCorvus Pharmaceuticals, Inc. (CRVS) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. Corvus Pharmaceuticals, Inc._July 21, 2026 0001626971 false 0001626971 2026-07-21 2026-07-21 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (
1 min readCorvus Pharmaceuticals said director David Scott Moore bought 21,700 common shares on June 11, 2026 via option exercise, according to a June 15 SEC Form 4. The weighted average purchase price was $11.53, with a $11.60 close price. Moore also holds 15,000 options at $11.60 that won’t vest until about a year later.
4 min readMoore David Scott purchased 21,700 shares of Corvus Pharmaceuticals, Inc. (CRVS) at $11.53 ($0.25M total) on 2026-06-11.
2 min readCorvus Pharmaceuticals, Inc. (CRVS) filed an SEC Form 8-K — Submission of Matters to a Vote of Security Holders. false 0001626971 0001626971 2026-06-11 2026-06-11 iso4217:USD xbrli:shares iso4217:USD xbrli:shares UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Repor
3 min readWall Street Zen has upgraded Corvus Pharmaceuticals (NASDAQ:CRVS) from a "sell" to a "hold" rating. The company currently holds a "Moderate Buy" consensus rating from analysts, with an average price target of $33.33. Despite missing quarterly earnings estimates, institutional investors have increased their stakes in the biopharmaceutical company.
3 min read
